Copyright
©The Author(s) 2022.
World J Cardiol. Jan 26, 2022; 14(1): 40-53
Published online Jan 26, 2022. doi: 10.4330/wjc.v14.i1.40
Published online Jan 26, 2022. doi: 10.4330/wjc.v14.i1.40
Table 2 Organization to Assess Strategies in Ischemic Syndromes 5: Primary efficacy and safety outcomes at 9 d
| Outcomes | Fondaparinux | Enoxaparin | HR (95%CI) | P value |
| Primary efficacy outcome: Cumulative event rate-Death, MI, refractory ischemia at 9 d | ||||
| Cumulative event rate | 5.80% | 5.70% | 1.01 (0.90-1.13) | 0.007 |
| Primary safety outcome: Major bleeding at 9 d | ||||
| Major bleeding | 2.20% | 4.10% | 0.52 (0.44-0.61) | P < 0.001 |
- Citation: Khan MY, Ponde CK, Kumar V, Gaurav K. Fondaparinux: A cornerstone drug in acute coronary syndromes. World J Cardiol 2022; 14(1): 40-53
- URL: https://www.wjgnet.com/1949-8462/full/v14/i1/40.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i1.40